Evaluation of hyperprolactinemia risk factors in infertile women referred to Yazd Infertility Center: A cross-sectional study
Background: Hyperprolactinemia is one of the most common causes of infertility in women. The prevalence of pituitary tumors is 25-30% among infertile participants with hyperprolactinemia.
Objective: The aim of this study was to describe the causes of hyperprolactinemia in infertile women referred to Yazd Infertility Center.
Materials and Methods: This cross-sectional study was conducted with 182 infertile women with hyperprolactinemia who were referred to Yazd Infertility Center from February 2018 to October 2019. Serum prolactin was assessed by the human prolactin ELISA kit according to the Padtan Gostar Isar protocol. The age, duration of infertility, causes of hyperprolactinemia, and type of infertility treatment were noted. The MRI findings were added.
Results: The mean age of participants was 28.9 ± 0.36 yr and the prolactin level was 76 ± 8.97 ng/ml. The etiology of hyperprolactinemia among the study participants was 35 participants (19.2%) with pituitary adenoma, 47 participants (25.8%) with polycystic ovary syndrome, 14 participants (7.7%) with pituitary adenoma and polycystic ovary syndrome, and 86 participants (47.3%) with idiopathic hyperprolactinemia. The results of this study showed that there was no statistically significant difference between the mean prolactin levels in participants with different causes of hyperprolactinemia (p = 0.31).
Conclusion: Idiopathic hyperprolactinemia and polycystic ovary syndrome are the most common reasons for hyperprolactinemia.
Key words: Hyperprolactinemia, Infertility, PCOS.
 Souter I, Baltagi LM, Toth ThL, Petrozza JC. Prevalence of hyperprolactinemia and abnormal magnetic resonance imaging findings in a population with infertility. Fertil Steril 2010; 94: 1159–1162.
 Soto-Pedre E, Newey PJ, Bevan JS, Greig N, Leese GP. The epidemiology of hyperprolactinaemia over 20 years in the Tayside region of Scotland: The prolactin epidemiology, audit and research study (PROLEARS). Clin Endocrinol 2017; 86: 60–67.
 Hattori N. Macroprolactinemia: A new cause of hyperprolactinemia. J Pharmacol Sci 2003; 92: 171– 177.
 Mancini T, Casanueva FF, Giustina A. Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin North Am 2008; 37: 67–99.
 Isah IA, Aliyu IS, Yusuf R, Isah HS, Randawa AJ, Adesiyun AG. Hyperprolactinemia and female infertility: Pattern of clinical presentation in a tertiary health facility in Northern Nigeria. Sahel Med J 2018; 21: 1–5.
 Bayrak A, Saadat P, Mor E, Chong L, Paulson RJ, Sokol RZ. Pituitary imaging is indicated for the evaluation of hyperprolactinemia. Fertil Steril 2005; 84: 181–185.
 Drange MR, Fram NR, Herman-Bonert V, Melmed S. Pituitary tumor registry: A novel clinical resource. J Clin Endocrinol Metab 2000; 85: 168–174.
 Goswami B, Patel S, Chatterjee M, Koner BC, Alpana S. Correlation of prolactin and thyroid hormone concentration with menstrual patterns in infertile women. J Reprod Infertil 2009; 10: 207–212.
 Zollner U, Lanig K, Steck T, Dietl J. Assessment of endocrine status in patients undergoing in-vitro fertilization treatment. Is it necessary? Arch Gynecol Obstet 2001; 265: 16–20.
 Mishra R, Baveja R, Gupta V, Gupta P. Prolactin level in infertility with menstrual irregularities. J Obstet Gynecol India 2002; 52: 40–43.
 Koyyada A, Orsu P. Role of hypothyroidism and associated pathways in pregnancy and infertility: Clinical insights. Tzu Chi Med J 2020; 32: 312–317.
 Wang AT, Mullan RJ, Lane MA, Hazem A, Prasad Ch, Gathaiya NW, et al. Treatment of hyperprolactinemia: A systematic review and meta-analysis. Syst Rev 2012; 1: 33.
 Ridha Barzanchi MT, Mahmmod SN, Al Omaly HLS. Effect of age, type and duration of infertility on prolactin concentration in the serum of hyperprolactinemic infertile women. J Facult Med Baghdad 2005; 47: 278–281.
 Aleyasin A, Aghahosseini M, Khademi A, Saeidi Saeid Abadi H. [Is hyperprolactinemia the main cause of infertility?] Tehran Univ Med J 1999; 57: 34–43. (in Persian)
 La Torre D, Falorni A. Pharmacological causes of hyperprolactinemia. Ther Clin Risk Manag 2007; 3: 929– 951.
 Goyal A, Ganie MA. Idiopathic hyperprolactinemia presenting as polycystic ovary syndrome in identical twin sisters: A case report and literature review. Cureus 2018; 10: e3004.
 Newey PJ, Gorvin CM, Thakker RV. Mutant prolactin receptor and familial hyperprolactinemia. N Engl J Med 2014; 370: 977–978.
 Crosignani PG. Management of hyperprolactinemic infertility. Middle East Fertil Soc J 2012; 17: 63–69.
 Filho RB, Domingues L, Naves L, Ferraz E, Alves A, Casulari LA. Polycystic ovary syndrome and hyperprolactinemia are distinct entities. Gynecol Endocrinol 2007; 23: 267–272.
 Hussein WI, Mustafa HEI, Khalil AB. Hyperprolactinemia and polycystic ovary syndrome: The debate continues. Ibnosina J Med Biomed Sci 2020; 12: 233–234.
 Delcour C, Robin G, Young J, Dewailly D. PCOS and hyperprolactinemia: What do we know in 2019? Clin Med Insights Reprod Health 2019; 13: 1179558119871921.
 Christin-Maître S, Delemer B, Touraine P, Young J. Prolactinoma and estrogens: Pregnancy, contraception and hormonal replacement therapy. Ann Endocrinol 2007; 68: 106–112.
 Tuzcu A, Bahceci M, Dursun M, Turgut C, Bahceci S. Insulin sensitivity and hyperprolactinemia. J Endocrinol Invest 2003; 26: 341–346.
 Bahceci M, Tuzcu A, Bahceci S, Tuzcu S. Is hyperprolactinemia associated with insulin resistance in non-obese patients with polycystic ovary syndrome? J Endocrinol Invest 2003; 26: 655–659.
 Kyritsi EM, Dimitriadis GK, Angelousi A, Mehta H, Shad A, Mytilinaiou M, et al. The value of prolactin in predicting prolactinoma in hyperprolactinaemic polycystic ovarian syndrome. Eur J Clin Invest 2018; 48: e12961.
 Destek S, Gul VO, Ahioglu S, Serin KR. Pituitary adenoma and hyperprolactinemia accompanied by idiopathic granulomatous mastitis. Case Rep Endocrinol 2017; 2017: 3974291.
 Altintoprak F, Kivilcim T, Ozkan OV. Aetiology of idiopathic granulomatous mastitis. World J Clin Cases 2014; 2: 852– 858.
 Lin ChH, Hsu ChW, Tsao TY, Chou J. Idiopathic granulomatous mastitis associated with risperidoneinduced hyperprolactinemia. Diagn Pathol 2012; 7: 2.